Rapport Therapeutics sees cash runway through 2026

The Company ended the fourth quarter with $305.3 million in cash, cash equivalents and short-term investments, compared to $320.7 million as of September 30, 2024. The decrease was primarily due to cash outflows on operating activities in the fourth quarter of 2024. The Company expects that cash, cash equivalents, and short-term investments as of December 31, 2024 will enable the Company to fund its operating expenses and capital expenditure requirements through the end of 2026.